Therapeutic Use of LSD in Psychiatry : A Systematic Review of Randomized-Controlled Clinical Trials
Fuentes, Juan José (Parc de Salut MAR de Barcelona)
Fonseca, Francina 1972- (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal)
Elices, M. (Parc de Salut MAR de Barcelona)
Farré Albaladejo, Magí (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Torrens, Marta (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal)

Data:	2020
Resum:	Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders. LSD was used in the treatment of anxiety, depression, psychosomatic diseases and addiction. However, most of the studies were not performed under contemporary standards, and it has taken several decades for a resurgence of interest in LSD research and its therapeutic potential for psychiatry. The aim of this review is to identify controlled and randomized clinical trials that assess the potential use of LSD in psychiatry. PRISMA guidelines for systematic review were followed. A literature search of PubMed and Psychedelic bibliography from Multidisciplinary Association for Psychedelic Studies (MAPS) databases was performed as well as a manual search of references from evaluated studies. Only randomized-controlled clinical trials were included. Study quality was systematically calculated by using the Cochrane Collaboration Tool for assessing risk of bias. A final selection of 11 articles was made after considering inclusion and exclusion criteria. LSD was administered to 567 patients in a dose ranging from 20 to 800 mcg. Despite the design heterogeneity of clinical trials, positive results were observed, thus revealing the therapeutic potential of LSD to reduce psychiatric symptomatology, mainly in alcoholism. The vast majority of authors describe significant and positive short-term changes in patients, despite the fact that in some studies an important homogenization was observed between the LSD treatment group and control group at long-term follow-up. Multiple variables regarding LSD treatment therapeutic approach and quality of experience were revealed and related to therapeutic outcomes. LSD is revealed as a potential therapeutic agent in psychiatry; the evidence to date is strongest for the use of LSD in the treatment of alcoholism. Despite the difficulty of designing proper double blind clinical trials with this substance, new studies that conform to modern standards are necessary in order to strengthen our knowledge on its use and open new doors in the future.
Ajuts:	Instituto de Salud Carlos III PI11-01961 Instituto de Salud Carlos III PI17-01962 Instituto de Salud Carlos III RD16-0017-0003 Instituto de Salud Carlos III RD16-0017-0010 Instituto de Salud Carlos III FJCI2017-31738 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-316 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-530 Agència de Gestió d'Ajuts Universitaris i de Recerca SLT006-17-00014
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article de revisió ; Article ; Versió publicada
Matèria:	Lysergic acid diethylamide (LSD) ; Hallucinogens ; Therapeutic use ; Psychiatric disorders ; Addiction
Publicat a:	Frontiers in psychiatry, Vol. 10 (january 2020) , ISSN 1664-0640

DOI: 10.3389/fpsyt.2019.00943
PMID: 32038315

14 p, 800.2 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles publicats